Abstract
Animal models represent the final step to complete preclinical investigations. Here, we describe in detail the principles and procedures for the surgical, toxin-induced animal models for Parkinson’s disease (PD), and Huntington’s disease (HD). Using highly precise stereotactic intracerebral injections of toxins into the nigrostriatal pathway and basal ganglia, we are able to target specific neural circuits in different regions of the dopaminergic and GABAergic system. In addition, validated protocols for adult and neonatal cell transplantation to reconstruct the destructed neuronal circuits as models for neural repair are described.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Horsley V, Clarke RH (1908) The structure and functions of the cerebellum examined by a new method. Brain 31:45–124
Paxinos G, Franklin K (2012) The mouse brain in stereotaxic coordinates. Academic Press, San Diego
Paxinos G, Franklin K (2006) The rat brain in stereotaxic coordinates. Academic Press, San Diego
Cenci MA, Whishaw IQ, Schallert T (2002) Animal models of neurological deficits: how relevant is the rat? Nat Rev Neurosci 3:574–579
Olanow CW (1993) A radical hypothesis for neurodegeneration. Trends Neurosci 16:439–444
Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson’s disease. Prog Neurobiol 65:135–172
Paxinos G, Watson C (2006) The rat brain in stereotaxic coordinates. Academic Press, San Diego
McGeer PL, Itagaki S, Akiyama H, McGeer EG (1988) Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 24:574–576
Amalric M, Moukhles H, Nieoullon A, Daszuta A (1995) Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat. Eur J Neurosci 7:972–980
Kirik D, Rosenblad C, Björklund A (1998) Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 152:259–277
Creese I, Burt DR, Snyder SH (1977) Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science 197:596–598
Marshall JF, Ungerstedt U (1977) Supersensitivity to apomorphine following destruction of the ascending dopamine neurons: quantification using the rotational model. Eur J Pharmacol 41:361–367
Dunnett SB, Robbins TW (1992) The functional role of mesotelencephalic dopamine systems. Biol Rev Camb Philos Soc 67:491–518
Dunnett SB, Björklund A, Schmidt RH, Stenevi U, Iversen SD (1983) Intracerebral grafting of neuronal cell suspensions. V. Behavioural recovery in rats with bilateral 6-OHDA lesions following implantation of nigral cell suspensions. Acta Physiol Scand Suppl 522:39–47
Dunnett SB (2010) Chapter 55: neural transplantation. Handb Clin Neurol 95:885–912
Goto S, Hirano A, Matsumoto S (1989) Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson’s disease and striatonigral degeneration. Ann Neurol 26:766–770
Carman LS, Gage FH, Shults CW (1991) Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior. Brain Res 553:275–283
van Oosten RV, Cools AR (2002) Differential effects of a small, unilateral, 6-hydroxydopamine-induced nigral lesion on behavior in high and low responders to novelty. Exp Neurol 173:245–255
Bentlage C, Nikkhah G, Cunningham MG, Björklund A (1999) Reformation of the nigrostriatal pathway by fetal dopaminergic micrografts into the substantia nigra is critically dependent on the age of the host. Exp Neurol 159:177–190
Nikkhah G, Cunningham MG, Cenci MA, McKay RD, Björklund A (1995) Dopaminergic microtransplants into the substantia nigra of neonatal rats with bilateral 6-OHDA lesions. I. Evidence for anatomical reconstruction of the nigrostriatal pathway. J Neurosci 15:3548–3561
Nikkhah G, Eberhard J, Olsson M, Björklund A (1995) Preservation of fetal ventral mesencephalic cells by cool storage: in-vitro viability and TH-positive neuron survival after microtransplantation to the striatum. Brain Res 687:22–34
Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi RE, Watkins PC, Ottina K, Wallace MR, Sakaguchi AY (1983) A polymorphic DNA marker genetically linked to Huntington’s disease. Nature 306:234–238
(1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. Cell 72:971–983.
Kieburtz K, MacDonald M, Shih C, Feigin A, Steinberg K, Bordwell K, Zimmerman C, Srinidhi J, Sotack J, Gusella J (1994) Trinucleotide repeat length and progression of illness in Huntington’s disease. J Med Genet 31:872–874
Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR (1997) The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 60:1202–1210
Borrell-Pagès M, Zala D, Humbert S, Saudou F (2006) Huntington’s disease: from huntingtin function and dysfunction to therapeutic strategies. Cell Mol Life Sci 63:2642–2660
Deng YP, Albin RL, Penney JB, Young AB, Anderson KD, Reiner A (2004) Differential loss of striatal projection systems in Huntington’s disease: a quantitative immunohistochemical study. J Chem Neuroanat 27:143–164
Nakamura K, Aminoff MJ (2007) Huntington’s disease: clinical characteristics, pathogenesis and therapies. Drugs Today (Barc) 43:97–116
Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB (1986) Replication of the neurochemical characteristics of Huntington’s disease by quinolinic acid. Nature 321:168–171
Bordelon YM, Chesselet MF, Nelson D, Welsh F, Erecińska M (1997) Energetic dysfunction in quinolinic acid-lesioned rat striatum. J Neurochem 69:1629–1639
Ribeiro CAJ, Grando V, Dutra Filho CS, Wannmacher CMD, Wajner M (2006) Evidence that quinolinic acid severely impairs energy metabolism through activation of NMDA receptors in striatum from developing rats. J Neurochem 99:1531–1542
Schwarcz R, Okuno E, White RJ, Bird ED, Whetsell WO (1988) 3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims. Proc Natl Acad Sci U S A 85:4079–4081
Beal MF, Matson WR, Swartz KJ, Gamache PH, Bird ED (1990) Kynurenine pathway measurements in Huntington’s disease striatum: evidence for reduced formation of kynurenic acid. J Neurochem 55:1327–1339
Beal MF, Ferrante RJ, Swartz KJ, Kowall NW (1991) Chronic quinolinic acid lesions in rats closely resemble Huntington’s disease. J Neurosci 11:1649–1659
Beal MF, Matson WR, Storey E, Milbury P, Ryan EA, Ogawa T, Bird ED (1992) Kynurenic acid concentrations are reduced in Huntington’s disease cerebral cortex. J Neurol Sci 108:80–87
Ferrante RJ, Kowall NW, Cipolloni PB, Storey E, Beal MF (1993) Excitotoxin lesions in primates as a model for Huntington’s disease: histopathologic and neurochemical characterization. Exp Neurol 119:46–71
Roberts RC, Ahn A, Swartz KJ, Beal MF, DiFiglia M (1993) Intrastriatal injections of quinolinic acid or kainic acid: differential patterns of cell survival and the effects of data analysis on outcome. Exp Neurol 124:274–282
Vazey EM, Chen K, Hughes SM, Connor B (2006) Transplanted adult neural progenitor cells survive, differentiate and reduce motor function impairment in a rodent model of Huntington’s disease. Exp Neurol 199:384–396
Döbrössy MD, Dunnett SB (2003) Motor training effects on recovery of function after striatal lesions and striatal grafts. Exp Neurol 184:274–284
Döbrössy MD, Dunnett SB (2006) The effects of lateralized training on spontaneous forelimb preference, lesion deficits, and graft-mediated functional recovery after unilateral striatal lesions in rats. Exp Neurol 199:373–383
Döbrössy MD, Dunnett SB (2006) Morphological and cellular changes within embryonic striatal grafts associated with enriched environment and involuntary exercise. Eur J Neurosci 24:3223–3233
Döbrössy MD, Dunnett SB (2007) The corridor task: striatal lesion effects and graft-mediated recovery in a model of Huntington’s disease. Behav Brain Res 179:326–330
Döbrössy MD, Svendsen CN, Dunnett SB (1996) Bilateral striatal lesions impair retention of an operant test of short-term memory. Brain Res Bull 41:159–165
Brasted PJ, Döbrössy MD, Robbins TW, Dunnett SB (1998) Striatal lesions produce distinctive impairments in reaction time performance in two different operant chambers. Brain Res Bull 46:487–493
Döbrössy MD, Svendsen CN, Dunnett SB (1995) The effects of bilateral striatal lesions on the acquisition of an operant test of short term memory. Neuroreport 6:2049–2053
Furtado JC, Mazurek MF (1996) Behavioral characterization of quinolinate-induced lesions of the medial striatum: relevance for Huntington’s disease. Exp Neurol 138:158–168
Isacson O, Brundin P, Kelly PA, Gage FH, Björklund A (1984) Functional neuronal replacement by grafted striatal neurones in the ibotenic acid-lesioned rat striatum. Nature 311:458–460
Shear DA, Dong J, Gundy CD, Haik-Creguer KL, Dunbar GL (1998) Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington’s disease. Prog Neuropsychopharmacol Biol Psychiatry 22:1217–1240
Cunningham MG, McKay RD (1993) A hypothermic miniaturized stereotaxic instrument for surgery in newborn rats. J Neurosci Methods 47:105–114
Jiang W, Büchele F, Papazoglou A, Döbrössy M, Nikkhah G (2009) Ketamine anaesthesia interferes with the quinolinic acid-induced lesion in a rat model of Huntington’s disease. J Neurosci Methods 179:219–223
Pruszak J, Just L, Isacson O, Nikkhah G (2009) Isolation and culture of ventral mesencephalic precursor cells and dopaminergic neurons from rodent brains. Curr Protoc Stem Cell Biol; Chapter 2:Unit 2D.5
Roedter A, Winkler C, Samii M, Walter GF, Brandis A, Nikkhah G (2001) Comparison of unilateral and bilateral intrastriatal 6-hydroxydopamine-induced axon terminal lesions: evidence for interhemispheric functional coupling of the two nigrostriatal pathways. J Comp Neurol 432:217–229
Nikkhah G, Cunningham MG, Jödicke A, Knappe U, Björklund A (1994) Improved graft survival and striatal reinnervation by microtransplantation of fetal nigral cell suspensions in the rat Parkinson model. Brain Res 633:133–143
Nikkhah G, Olsson M, Eberhard J, Bentlage C, Cunningham MG, Björklund A (1994) A microtransplantation approach for cell suspension grafting in the rat Parkinson model: a detailed account of the methodology. Neuroscience 63:57–72
Nikkhah G, Rosenthal C, Falkenstein G, Roedter A, Papazoglou A, Brandis A (2009) Microtransplantation of dopaminergic cell suspensions: further characterization and optimization of grafting parameters. Cell Transplant 18:119–133
Hahn M, Timmer M, Nikkhah G (2009) Survival and early functional integration of dopaminergic progenitor cells following transplantation in a rat model of Parkinson’s disease. J Neurosci Res 87:2006–2019
Brandis A, Kuder H, Knappe U, Jödicke A, Schönmayr R, Samii M, Walter GF, Nikkhah G (1998) Time-dependent expression of donor- and host-specific major histocompatibility complex class I and II antigens in allogeneic dopamine-rich macro- and micrografts: comparison of two different grafting protocols. Acta Neuropathol (Berl) 95:85–97
Steiner B, Winter C, Blumensath S, Paul G, Harnack D, Nikkhah G, Kupsch A (2008) Survival and functional recovery of transplanted human dopaminergic neurons into hemiparkinsonian rats depend on the cannula size of the implantation instrument. J Neurosci Methods 169:128–134
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Maciaczyk, J., Kahlert, U.D., Döbrössy, M., Nikkhah, G. (2016). Stereotactic Surgery in Rats. In: Janowski, M. (eds) Experimental Neurosurgery in Animal Models. Neuromethods, vol 116. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3730-1_3
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3730-1_3
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3728-8
Online ISBN: 978-1-4939-3730-1
eBook Packages: Springer Protocols